Conditions: Renal Transplant
Keywords: QoL GI Side Effects MPA
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 134
Healthy volunteers: no

Brief summary:
This open, multi-center randomized controlled study is designed to investigate the quality of life in patients with mycophenolate mofetil (MMF)-induced gastrointestinal (GI) adverse events after converting to enteric-coated mycophenolate sodium (EC-MPS).

Detailed description:

Arms:
arm 1: 250 mg capsules or 500 mg tablets of mycophenolate mofetil. Daily dose decided by physician, was taken morning and evening. arm 2: Oral film-coated gastroresistant tablets containing 360mg or 180mg of mycophenolate sodium. Daily dose decided by the physician, was taken morning and evening.

Interventions: intervention 1: Enteric-Coated Mycophenolate Sodium (EC-MPS) intervention 2: Mycophenolate Mofetil (MMF)
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: